Literature DB >> 17182747

Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts.

Mark L Quinlivan1, Anne A Gershon, Mahmoud M Al Bassam, Sharon P Steinberg, Philip LaRussa, Richard A Nichols, Judith Breuer.   

Abstract

The Oka vaccine strain is a live attenuated virus that is routinely administered to children in the United States and Europe to prevent chickenpox. It is effective and safe but occasionally produces a rash. The vaccine virus has accumulated mutations during its attenuation, but the rashes are not explained by their reversion, unlike complications reported for other viral vaccines. Indeed, most of the novel mutations distinguishing the Oka vaccine from the more virulent parental virus have not actually become fixed. Because the parental alleles are still present, the vaccine is polymorphic at >30 loci and therefore contains a mixture of related viruses. The inoculation of >40 million patients has consequently created a highly replicated evolutionary experiment that we have used to assess the competitive ability of these different viral genotypes in a human host. Using virus recovered from rash vesicles, we show that two vaccine mutations, causing amino acid substitutions in the major transactivating protein IE62, are outcompeted by the ancestral alleles. Standard interpretations of varicella disease severity concentrate on the undeniably important effects of host genotype and immune status, yet our results allow us to demonstrate that the viral genotype is associated with virulence and to identify the key sites. We propose that these loci have pleiotropic effects on the immunogenic properties of the virus, rash formation, and its epidemiological spread, which mould the evolution of its virulence. These findings are of practical importance for reducing the incidence of vaccine-associated rash and promoting public acceptance of the vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182747      PMCID: PMC1765436          DOI: 10.1073/pnas.0605688104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Consensus: varicella vaccination of healthy children--a challenge for Europe.

Authors:  Bernard Rentier; Anne A Gershon
Journal:  Pediatr Infect Dis J       Date:  2004-05       Impact factor: 2.129

2.  Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus.

Authors:  Mark L Quinlivan; Anne A Gershon; Sharon P Steinberg; Judith Breuer
Journal:  J Infect Dis       Date:  2004-07-15       Impact factor: 5.226

3.  Development of a live attenuated varicella vaccine.

Authors:  M Takahashi; Y Okuno; T Otsuka; J Osame; A Takamizawa
Journal:  Biken J       Date:  1975-03

4.  Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

Authors:  G D Westrop; K A Wareham; D M Evans; G Dunn; P D Minor; D I Magrath; F Taffs; S Marsden; M A Skinner; G C Schild
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells.

Authors:  Ofer Levy; Jordan S Orange; Patricia Hibberd; Sharon Steinberg; Phillip LaRussa; Adriana Weinberg; S Brian Wilson; Angela Shaulov; Gary Fleisher; Raif S Geha; Francisco A Bonilla; Mark Exley
Journal:  J Infect Dis       Date:  2003-09-26       Impact factor: 5.226

6.  Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child.

Authors:  Myron J Levin; Karen M Dahl; Adriana Weinberg; Roger Giller; Amita Patel; Philip R Krause
Journal:  J Infect Dis       Date:  2003-09-26       Impact factor: 5.226

7.  The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group.

Authors:  I Hardy; A A Gershon; S P Steinberg; P LaRussa
Journal:  N Engl J Med       Date:  1991-11-28       Impact factor: 91.245

8.  Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination.

Authors:  Christian R Frey; Margaret A Sharp; Andrew S Min; D Scott Schmid; Vladimir Loparev; Ann M Arvin
Journal:  J Infect Dis       Date:  2003-06-23       Impact factor: 5.226

9.  Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo.

Authors:  Bunji Sato; Hideki Ito; Stewart Hinchliffe; Marvin H Sommer; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

10.  Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse.

Authors:  J F Moffat; L Zerboni; P R Kinchington; C Grose; H Kaneshima; A M Arvin
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

View more
  15 in total

1.  Varicella-zoster vaccine virus: evolution in action.

Authors:  Jeffrey I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

2.  Mutational analysis of varicella-zoster virus (VZV) immediate early protein (IE62) subdomains and their importance in viral replication.

Authors:  Mohamed I Khalil; Xibing Che; Phillip Sung; Marvin H Sommer; John Hay; Ann M Arvin
Journal:  Virology       Date:  2016-02-23       Impact factor: 3.616

3.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

4.  Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions.

Authors:  Sonja Thiele; Aljona Borschewski; Judit Küchler; Marc Bieberbach; Sebastian Voigt; Bernhard Ehlers
Journal:  Clin Vaccine Immunol       Date:  2011-05-11

5.  Population diversity in batches of the varicella Oka vaccine.

Authors:  R K Kanda; M L Quinlivan; A A Gershon; R A Nichols; J Breuer
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

6.  A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture.

Authors:  Aruna P N Ambagala; Tammy Krogmann; Jing Qin; Lesley Pesnicak; Jeffrey I Cohen
Journal:  Virology       Date:  2010-02-08       Impact factor: 3.616

7.  Severe complications of chickenpox in hospitalised children in the UK and Ireland.

Authors:  J C Cameron; G Allan; F Johnston; A Finn; P T Heath; R Booy
Journal:  Arch Dis Child       Date:  2007-11-08       Impact factor: 3.791

8.  Dengue virus evolution and virulence models.

Authors:  Rebeca Rico-Hesse
Journal:  Clin Infect Dis       Date:  2007-04-18       Impact factor: 9.079

9.  Complete DNA sequences of two oka strain varicella-zoster virus genomes.

Authors:  Sueli L Tillieux; Wendy S Halsey; Elizabeth S Thomas; John J Voycik; Ganesh M Sathe; Ventzislav Vassilev
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

10.  Transmission of varicella vaccine virus, Japan.

Authors:  Taketo Otsuka; Yasuyuki Gomi; Naoki Inoue; Makoto Uchiyama
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.